UNLABELLED: PET-based treatment response assessment typically measures the change in maximum standardized uptake value (SUV(max)), which is adversely affected by noise. Peak SUV (SUV(peak)) has been recommended as a more robust alternative, but its associated region of interest (ROI(peak)) is not uniquely defined. We investigated the impact of different ROI(peak) definitions on quantification of SUV(peak) and tumor response. METHODS: Seventeen patients with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor resulting in a variety of responses. Using the cellular proliferation marker 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT), whole-body PET/CT scans were acquired at baseline and during treatment. (18)F-FLT-avid lesions (∼2/patient) were segmented on PET images, and tumor response was assessed via the relative change in SUV(peak). For each tumor, 24 different SUV(peaks) were determined by changing ROI(peak) shape (circles vs. spheres), size (7.5-20 mm), and location (centered on SUV(max) vs. placed in highest-uptake region), encompassing different definitions from the literature. Within each tumor, variations in the 24 SUV(peaks) and tumor responses were measured using coefficient of variation (CV), standardized deviation (SD), and range. For each ROI(peak) definition, a population average SUV(peak) and tumor response were determined over all tumors. RESULTS: A substantial variation in both SUV(peak) and tumor response resulted from changing the ROI(peak) definition. The variable ROI(peak) definition led to an intratumor SUV(peak) variation ranging from 49% above to 46% below the mean (CV, 17%) and an intratumor SUV(peak) response variation ranging from 49% above to 35% below the mean (SD, 9%). The variable ROI(peak) definition led to a population average SUV(peak) variation ranging from 24% above to 28% below the mean (CV, 14%) and a population average SUV(peak) response variation ranging from only 3% above to 3% below the mean (SD, 2%). The size of ROI(peak) caused more variation in intratumor response than did the location or shape of ROI(peak). Population average tumor response was independent of size, shape, and location of ROI(peak). CONCLUSION: Quantification of individual tumor response using SUV(peak) is highly sensitive to the ROI(peak) definition, which can significantly affect the use of SUV(peak) for assessment of treatment response. Clinical trials are necessary to compare the efficacy of SUV(peak) and SUV(max) for quantification of response to therapy.
UNLABELLED: PET-based treatment response assessment typically measures the change in maximum standardized uptake value (SUV(max)), which is adversely affected by noise. Peak SUV (SUV(peak)) has been recommended as a more robust alternative, but its associated region of interest (ROI(peak)) is not uniquely defined. We investigated the impact of different ROI(peak) definitions on quantification of SUV(peak) and tumor response. METHODS: Seventeen patients with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor resulting in a variety of responses. Using the cellular proliferation marker 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT), whole-body PET/CT scans were acquired at baseline and during treatment. (18)F-FLT-avid lesions (∼2/patient) were segmented on PET images, and tumor response was assessed via the relative change in SUV(peak). For each tumor, 24 different SUV(peaks) were determined by changing ROI(peak) shape (circles vs. spheres), size (7.5-20 mm), and location (centered on SUV(max) vs. placed in highest-uptake region), encompassing different definitions from the literature. Within each tumor, variations in the 24 SUV(peaks) and tumor responses were measured using coefficient of variation (CV), standardized deviation (SD), and range. For each ROI(peak) definition, a population average SUV(peak) and tumor response were determined over all tumors. RESULTS: A substantial variation in both SUV(peak) and tumor response resulted from changing the ROI(peak) definition. The variable ROI(peak) definition led to an intratumor SUV(peak) variation ranging from 49% above to 46% below the mean (CV, 17%) and an intratumor SUV(peak) response variation ranging from 49% above to 35% below the mean (SD, 9%). The variable ROI(peak) definition led to a population average SUV(peak) variation ranging from 24% above to 28% below the mean (CV, 14%) and a population average SUV(peak) response variation ranging from only 3% above to 3% below the mean (SD, 2%). The size of ROI(peak) caused more variation in intratumor response than did the location or shape of ROI(peak). Population average tumor response was independent of size, shape, and location of ROI(peak). CONCLUSION: Quantification of individual tumor response using SUV(peak) is highly sensitive to the ROI(peak) definition, which can significantly affect the use of SUV(peak) for assessment of treatment response. Clinical trials are necessary to compare the efficacy of SUV(peak) and SUV(max) for quantification of response to therapy.
Authors: Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga Journal: Eur J Nucl Med Mol Imaging Date: 2004-12 Impact factor: 9.236
Authors: Betty S Pio; Cecilia K Park; Richard Pietras; Wei-Ann Hsueh; Nagichettiar Satyamurthy; Mark D Pegram; Johannes Czernin; Michael E Phelps; Daniel H S Silverman Journal: Mol Imaging Biol Date: 2006 Jan-Feb Impact factor: 3.488
Authors: S J Martin; J A Eisenbarth; U Wagner-Utermann; W Mier; M Henze; H Pritzkow; U Haberkorn; M Eisenhut Journal: Nucl Med Biol Date: 2002-02 Impact factor: 2.408
Authors: Eva Brun; Elisabeth Kjellén; Jan Tennvall; Tomas Ohlsson; Anders Sandell; Roland Perfekt; Roland Perfekt; Johan Wennerberg; Sven Erik Strand Journal: Head Neck Date: 2002-02 Impact factor: 3.147
Authors: S Stroobants; J Goeminne; M Seegers; S Dimitrijevic; P Dupont; J Nuyts; M Martens; B van den Borne; P Cole; R Sciot; H Dumez; S Silberman; L Mortelmans; A van Oosterom Journal: Eur J Cancer Date: 2003-09 Impact factor: 9.162
Authors: Andreas K Buck; Clemens Kratochwil; Gerhard Glatting; Malik Juweid; Martin Bommer; Djurdja Tepsic; Andreas T J Vogg; Torsten Mattfeldt; Bernd Neumaier; Peter Möller; Sven N Reske Journal: Eur J Nucl Med Mol Imaging Date: 2007-05-31 Impact factor: 9.236
Authors: Kristen A Wangerin; Mark Muzi; Lanell M Peterson; Hannah M Linden; Alena Novakova; David A Mankoff; Paul E Kinahan Journal: Phys Med Biol Date: 2017-02-13 Impact factor: 3.609
Authors: Christian Philipp Reinert; Martin Ulrich Schuhmann; Benjamin Bender; Isabel Gugel; Christian la Fougère; Jürgen Schäfer; Sergios Gatidis Journal: Eur J Nucl Med Mol Imaging Date: 2018-12-08 Impact factor: 9.236
Authors: Mathieu Hatt; John A Lee; Charles R Schmidtlein; Issam El Naqa; Curtis Caldwell; Elisabetta De Bernardi; Wei Lu; Shiva Das; Xavier Geets; Vincent Gregoire; Robert Jeraj; Michael P MacManus; Osama R Mawlawi; Ursula Nestle; Andrei B Pugachev; Heiko Schöder; Tony Shepherd; Emiliano Spezi; Dimitris Visvikis; Habib Zaidi; Assen S Kirov Journal: Med Phys Date: 2017-05-18 Impact factor: 4.071
Authors: Robert K Doot; Anthony J Young; Margaret E Daube-Witherspoon; David Alexoff; Kyle J Labban; Hwan Lee; Zehui Wu; Zhihao Zha; Seok R Choi; Karl H Ploessl; Erin K Schubert; Hsiaoju Lee; Lin Zhu; Janet S Reddin; Joel S Karp; Hank Kung; Daniel A Pryma Journal: Nucl Med Biol Date: 2020-04-20 Impact factor: 2.408
Authors: Mitchell Machtay; Fenghai Duan; Barry A Siegel; Bradley S Snyder; Jeremy J Gorelick; Janet S Reddin; Reginald Munden; Douglas W Johnson; Larry H Wilf; Albert DeNittis; Nancy Sherwin; Kwan Ho Cho; Seok-Ki Kim; Gregory Videtic; Donald R Neumann; Ritsuko Komaki; Homer Macapinlac; Jeffrey D Bradley; Abass Alavi Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Sara Carvalho; Ralph T H Leijenaar; Emmanuel Rios Velazquez; Cary Oberije; Chintan Parmar; Wouter van Elmpt; Bart Reymen; Esther G C Troost; Michel Oellers; Andre Dekker; Robert Gillies; Hugo J W L Aerts; Philippe Lambin Journal: Acta Oncol Date: 2013-09-09 Impact factor: 4.089